

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

Mouse Anti-CD16 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 3G8

RRID:AB_396941

Type: Antibody

Proper Citation

BD Biosciences Cat# 557920, RRID:AB_396941

Antibody Information

URL: http://antibodyregistry.org/AB_396941

Proper Citation: BD Biosciences Cat# 557920, RRID:AB_396941

Target Antigen: CD16 (FcγRIII)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-CD16 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 3G8

Description: This monoclonal targets CD16 (FcγRIII)

Target Organism: baboon, cynomolgus, rhesus, human

Clone ID: Clone 3G8

Antibody ID: AB_396941

Vendor: BD Biosciences

Catalog Number: 557920

Record Creation Time: 20250819T214357+0000

Record Last Update: 20250819T235447+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD16 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 3G8.

No alerts have been found for Mouse Anti-CD16 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 3G8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell reports methods, 5(5), 101049.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. Cell reports methods, 3(1), 100388.

Nogimori T, et al. (2022) Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Frontiers in immunology, 13, 1081047.

Ramaswamy A, et al. (2021) Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity, 54(5), 1083.

Choi J, et al. (2021) Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. Cell reports methods, 1(5), 100084.